IP Library Granted Patent US 10,322,170
Granted Patent B2
US 10,322,170 · App. 15/080,026 · Granted Jun 18, 2019

Hemostatic compositions

Inventors: Heinz Gulle (Gross Enzersdorf, AT); Joris Hoefinghoff (Vienna, AT); Andreas Goessl (Vienna, AT); Katarzyna Gorna (Vienna, AT)
Assignees: Baxter International Inc.; Baxter Healthcare SA
A61K38/39A61K9/06A61K9/14A61K31/77A61K35/32A61K47/34A61L24/0031A61L24/043A61L26/008A61L26/0052A61L26/0066A61K47/10A61K47/42A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,170
App. No.
15/080,026
Granted
Jun 18, 2019
Kind
B2
Abstract

The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.

Claims (12)

1. A method for producing a hemostatic composition in paste form for treating a patient, the composition comprising a crosslinked gelatin, wherein the crosslinked gelatin is present as granular particles having a median particle size range of 50 μm to 700 μm, and an equilibrium swell within a range from 400% to 1300%; one polyalkylene oxide polymer comprising electrophilic reactive groups selected from the group consisting of NHS-ester groups, imidoester groups, aldehyde-groups, carboxy-groups in the presence of carbodiimides, isocyanates, and beta-[tris(hydroxymethyl)phosphino]propionic acid (THPP); and a binder that does not react with the electrophilic reactive groups of the one polyalkylene oxide polymer; wherein the hemostatic composition is free from a second or further polyalkylene oxide polymers comprising electrophilic reactive groups, the method comprising:

mixing the crosslinked gelatin and the one polyalkylene oxide polymer comprising electrophilic reactive groups with the binder, wherein the electrophilic reactive groups of the one polyalkylene oxide polymer retain their reactivity until the composition is exposed to blood of the patient, wherein the electrophilic reactive groups are configured to cross-link with blood proteins of the patient to form a gel with sealing and hemostatic properties.

2. The method according to claim 1 , wherein the mixing step comprises first mixing the crosslinked gelatin with the one polyalkylene oxide polymer comprising electrophilic reactive groups to obtain a homogeneous mixture of the crosslinked gelatin and the one polyalkylene oxide polymer comprising electrophilic reactive groups, and then mixing the binder with the homogeneous mixture to obtain the hemostatic composition in paste form.

3. The method according to claim 1 , wherein the binder comprises a Poloxamer.

4. The method according to claim 3 , wherein the Poloxamer is ethylene oxide(2)/propylene oxide(32)/ethylene oxide(2).

5. The method according to claim 1 , wherein the one polyalkylene oxide polymer with electrophilic reactive groups is a polyethylene glycol (PEG).

6. The method according to claim 5 , wherein the polyethylene glycol (PEG) comprises two or more electrophilic reactive groups selected from succinimidyl esters (—CON(COCH 2 ) 2 ), aldehydes (—CHO) and isocyanates (—N═C═O).

7. The method according to claim 1 , wherein the polyalkylene oxide polymer is pentaerythritolpoly(ethyleneglycol)ether tetrasuccinimidyl glutarate.

8. The method according to claim 1 , wherein the binder contains or is a substance selected from the group consisting of glycerol, a derivative of glycerol, DMSO, ethanol, a polyethyleneglycol, a Poloxamer, and combinations thereof.

9. The method according to claim 1 , wherein the binder has a water content (% v/v) below 5%.

10. The method according to claim 9 , wherein the water content (% v/v) is below 2%.

11. The method according to claim 9 , wherein the water content (% v/v) is below 1%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2016
From: GULLE, HEINZ; GOESSL, ANDREAS; GORNA, KATARZYNA; HOEFINGHOFF, JORIS
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 038100/0820 →
Continuity (3)
Continuation 13648885 · Oct 10, 2012
Provisional Application 61545926 · Oct 11, 2011
Related Publication 20160271228A1 · Sep 22, 2016
Cited By (1)
US 12,343,385